摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

(S)-4-Morpholin-4-yl-3-(naphthalene-2-sulfonylamino)-4-oxo-butyric acid | 140646-12-4

中文名称
——
中文别名
——
英文名称
(S)-4-Morpholin-4-yl-3-(naphthalene-2-sulfonylamino)-4-oxo-butyric acid
英文别名
(3S)-4-morpholin-4-yl-3-(naphthalen-2-ylsulfonylamino)-4-oxobutanoic acid
(S)-4-Morpholin-4-yl-3-(naphthalene-2-sulfonylamino)-4-oxo-butyric acid化学式
CAS
140646-12-4
化学式
C18H20N2O6S
mdl
——
分子量
392.433
InChiKey
MOSUHGVMXJFVDS-INIZCTEOSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    0.8
  • 重原子数:
    27
  • 可旋转键数:
    6
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.33
  • 拓扑面积:
    121
  • 氢给体数:
    2
  • 氢受体数:
    7

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    (S)-4-Morpholin-4-yl-3-(naphthalene-2-sulfonylamino)-4-oxo-butyric acid 、 (RS)-3-(aminomethyl)piperidine-1-carboxamidine dihydrochloride 在 N-乙基吗啉 、 dowex 、 盐酸 、 (benzotriazo-1-yloxy)tris(dimethylamino)phosphonium hexafluorophosphate 作用下, 生成 (3S)-N-[(1-carbamimidoylpiperidin-3-yl)methyl]-4-morpholin-4-yl-3-(naphthalen-2-ylsulfonylamino)-4-oxobutanamide;hydrochloride
    参考文献:
    名称:
    Design and Synthesis of Potent and Highly Selective Thrombin Inhibitors
    摘要:
    Thrombin, a serine protease, plays a central role in the initiation and propagation of thrombotic events. An extensive search for new thrombin inhibitors was performed, using an unconventional approach. Screening of small basic molecules for binding in the recognition pocket of thrombin led to the discovery of (aminoiminomethyl)piperidine (amidinopiperidine) as a weak, but intrinsically selective, thrombin inhibitor. Elaboration of this molecule provided compounds which inhibit thrombin with K-i's in the range of 20-50 nM and with selectivities of 1000-4000 against trypsin. These inhibitor compounds show a new and unexpected, binding mode to thrombin. Modification of the central building block and then of one of the hydrophobic substituents led to the discovery of a new family of thrombin inhibitors which has reverted td the former binding mode to thrombin. This last class of compounds shows inhibitory activities in the picomolar range; low toxicity; and a short plasma half life which favors its use for an intravenous application. From this series of thrombin;inhibitors, 19f (Ro 46-6240) was selected for clinical development as an antithrombotic agent for intravenous administration.
    DOI:
    10.1021/jm00049a008
  • 作为产物:
    描述:
    benzyl (3S)-3-[(2-methylpropan-2-yl)oxycarbonylamino]-4-morpholin-4-yl-4-oxobutanoate 在 palladium on activated charcoal 盐酸sodium hydroxide氢气 作用下, 以 1,4-二氧六环乙醇二氯甲烷乙酸乙酯 为溶剂, 25.0 ℃ 、100.0 kPa 条件下, 反应 11.0h, 生成 (S)-4-Morpholin-4-yl-3-(naphthalene-2-sulfonylamino)-4-oxo-butyric acid
    参考文献:
    名称:
    Design and Synthesis of Potent and Highly Selective Thrombin Inhibitors
    摘要:
    Thrombin, a serine protease, plays a central role in the initiation and propagation of thrombotic events. An extensive search for new thrombin inhibitors was performed, using an unconventional approach. Screening of small basic molecules for binding in the recognition pocket of thrombin led to the discovery of (aminoiminomethyl)piperidine (amidinopiperidine) as a weak, but intrinsically selective, thrombin inhibitor. Elaboration of this molecule provided compounds which inhibit thrombin with K-i's in the range of 20-50 nM and with selectivities of 1000-4000 against trypsin. These inhibitor compounds show a new and unexpected, binding mode to thrombin. Modification of the central building block and then of one of the hydrophobic substituents led to the discovery of a new family of thrombin inhibitors which has reverted td the former binding mode to thrombin. This last class of compounds shows inhibitory activities in the picomolar range; low toxicity; and a short plasma half life which favors its use for an intravenous application. From this series of thrombin;inhibitors, 19f (Ro 46-6240) was selected for clinical development as an antithrombotic agent for intravenous administration.
    DOI:
    10.1021/jm00049a008
点击查看最新优质反应信息

文献信息

  • US5260307A
    申请人:——
    公开号:US5260307A
    公开(公告)日:1993-11-09
  • US5393760A
    申请人:——
    公开号:US5393760A
    公开(公告)日:1995-02-28
  • US5532232A
    申请人:——
    公开号:US5532232A
    公开(公告)日:1996-07-02
  • US5583133A
    申请人:——
    公开号:US5583133A
    公开(公告)日:1996-12-10
  • US5595999A
    申请人:——
    公开号:US5595999A
    公开(公告)日:1997-01-21
查看更多